Novo Nordisk Boosts Wegovy Access With Lower Pricing and Home Delivery

On Wednesday, Novo Nordisk A/S NVO introduced NovoCare Pharmacy, a direct-to-patient delivery service to improve access to Wegovy (semaglutide) for cash-paying patients.

The program offers all dosage strengths of the weight-loss medication at a reduced price of $499 per month for uninsured individuals or those whose insurance does not cover obesity treatments.

Last year, Drugmaker Eli Lilly And Co LLY announced a new website allowing patients to get a prescription for weight loss through a telehealth provider, marking an industry first.

This initiative follows the FDA's declaration that the Wegovy shortage has been resolved, ensuring supply meets current and projected demand in the U.S.

Last week, the compounding groups Outsourcing Facilities Association (OFA) and FarmaKeio Superior Custom Compounding filed a lawsuit challenging the FDA's decision to remove semaglutide from the drug shortage list.

Dave Moore, Executive Vice President of U.S. Operations and Global Business Development at Novo Nordisk, noted that while over 55 million Americans have coverage for weight management treatments, 90% of insured Wegovy users pay between $0 and $25 per month.

Also Read: AbbVie Becomes Another Big Pharma To Enter Obesity Treatment Race

NovoCare Pharmacy allows cash-paying patients to receive home deliveries of prescribed Wegovy doses, facilitated by CenterWell Pharmacy, a six-time Specialty Pharmacy Patient Choice award winner. Patients also benefit from refill reminders, benefit verification, and live support from NovoCare case managers.

The company says the service helps mitigate risks associated with compounded semaglutide products, which the FDA and medical experts have warned could pose safety concerns.

Last month, Eli Lilly launched 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, available for $499 with the new Zepbound Self Pay Journey Program. Eli Lilly also reduced the price of the 2.5 mg and 5 mg vials.

These new offerings are available exclusively through LillyDirect Self-Pay Pharmacy Solutions, which enables a transparent price by removing third-party supply chain entities and allowing patients to access savings directly outside of insurance.

Price Action: NVO stock is up 4.30% at $91.26 at the last check on Wednesday.

Read Next:

• Foot Locker Q4 Earnings: EPS Beat, Sales Miss, Comps Up 2.6%, Margin Expansion And More

Photo by Tobias Arhelger via Shutterstock